rare side effects of semaglutide Exploring the GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning What are the long-term side
Description
Mol Metab 47:101180
This ensures that each patient receives safe, effective, and individualized care
A 2021 study published in the New England Journal of Medicine found that semaglutide 0.4 mg daily led to resolution of non-alcoholic steatohepatitis (NASH) in 59% of participants compared to 17% in the placebo group
However, animal studies indicate a potential risk to the fetus (unborn baby)
Always consult with your healthcare provider for personalized advice
